Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Results reported from phase II OvaRex ovarian cancer trial

Aug. 1, 2001

High proportion of complete remissions obtained in hairy cell leukemia with new immunotoxin

July 30, 2001

Promising results reported from Multikine study in HPV-induced cervical dysplasia

July 26, 2001

SciClone's lead ISE approved for cancer indication in the Philippines

July 24, 2001

Safety of vaccination with ALVAC vector-expressed p53 in primates

July 24, 2001

Arius Research begins preparations for phase I clinical trials of cancer-killing antibodies

July 20, 2001

Mechanism of action of Mylotarg in AML elucidated

July 20, 2001

Licensing opportunity from NIH: beta2-microglobulin fusion proteins

July 17, 2001

Positive long-term survival and safety data reported for OvaRex

July 16, 2001

MabCampath approved in Europe for B-CLL

July 13, 2001

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...